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1356Autologous Hematopoietic Stem Cell Transplantation
in Extranodal Natural Killer/T Cell Lymphoma: A
Multinational, Multicenter, Matched Controlled Study
Jeeyun Lee,1 Wing-Yan Au,2 Min Jae Park,1 Junji Suzumiya,3 Shigeo Nakamura,4
Jun-Ichi Kameoka,5 Chikara Sakai,6 Kazuo Oshimi,7 Yok-Lam Kwong,2 Raymond Liang,2
Harry Yiu,8 Kam-Hung Wong,8 Hoi-Ching Cheng,8 Baek-Yeol Ryoo,9 Cheolwon Suh,10
Young Hyeh Ko,11 Kihyun Kim,1 Jae-Won Lee,12 Won Seog Kim,1 Ritsuro Suzuki13Extranodal natural killer (NK)/T cell lymphoma, nasal type, is a recently recognized distinct entity and the
most common type of non–B cell extranodal lymphoma in Asia. This retrospective analysis studied the
potential survival benefits of hematopoeitic stem cell transplantation (HSCT) compared with a historical
control group. A total of 47 patients from 3 previously published series of HSCT were matched according
to NK/T cell lymphoma International Prognostic Index (NKIPI) risk groups and disease status at transplan-
tation with 107 patients from a historical control group for analysis. After a median follow-up of 116.5
months, the median survival time was not determined for the HSCT group, but it was 43.5 months for
the control group (95% confidence interval [CI] 5 6.7 to 80.3 months; P 5 .127, log-rank test). In patients
who were in complete remission (CR) at the time of HSCTor at surveillance after remission, disease-specific
survival rates were significantly higher in the HSCT group compared with the control group (disease-specific
5-year survival rate, 87.3% for HSCT vs 67.8% for non-HSCT; P5 .027). In contrast, in subgroup analysis on
non-CR patients at the time of HSCT or non-HSCT treatment, disease-specific survival rates were not
significantly prolonged in the HSCT group compared with the control group (1-year survival rate, 66.7%
for HSCT vs 28.6% for non-HSCT; P 5 .141). The impact of HSCTon the survival of all patients was signif-
icantly retained at the multivariate level with a 2.1-fold (95% CI 51.2- to 3.7-fold) reduced risk of death
(P 5 .006). HSCT seems to confer a survival benefit in patients who attained CR on postremission consol-
idation therapy. These findings suggest that, in particular, patients in CR with high NKIPI risk scores at diag-
nosis should receive full consideration for HSCT.
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most common type of non–B cell extranodal lym-
phoma in Asia [2]. The treatment outcome for NK/
T cell lymphomas depends on disease stage. Overall,
long-term survival in these lymphomas, reported as
30% to 40% [3-6], tends to be inferior to that for other
aggressive lymphomas. Even in localized NK/T cell
lymphomas, primary chemotherapy and/or radiother-
apy (RT) results in complete remission (CR) rates of
40% to 60%, with 5-year overall survival (OS) rates
of 42% to 83% [3,4,7-11], with high systemic failure
rates of 25% to 30% [7-9,12].
In an effort to identify strategies for improving
these low success rates in treating NK/T cell lym-
phoma, the use of high-dose chemotherapy (HDC)
and autologous hematopoietic stem cell transplanta-
tion (HSCT) has been investigated [13-17]. Determin-
ing the survival benefit ofHSCTbased on the results of
these studies is difficult, however, because of the small
size as well as the heterogeneous nature of the patient
cohorts.
Recently, a prognostic model specific for NK/T
cell lymphoma (NK/T cell lymphoma International
Prognostic Index [NKIPI]) has been proposed and val-
idated [6,18]. Clinical variables included in the NKIPI
risk scoring system are B symptoms, stage, lactic dehy-
drogenase (LDH) level, and regional lymphadenopa-
thies. Owing to its extranodal characteristics, the
prognostic impact of the IPI has been controversial in
this particular subtype of non-Hodgkin lymphoma
(NHL). Similar to other prognostic models, the NK-
IPI has the major aim of identifying high-risk patients
and thereby provide better risk-based stratification
for optimal treatment.
To explore the potential benefits of autologous
HSCT, we have pooled and reanalyzed data from 3
previously published series [6,13,14]. To critically
evaluate the role of autologous HSCT, we compared
those results with those for a matched control group
identified from historical data.
PATIENTS AND METHODS
Patients and Data Collection
Our cohort comprises 59 patients with NK/T cell
lymphomas who underwent autologous HSCT re-
ported in 3 previous studies from Korea, Hong
Kong, and Japan [6,13,14]. From these 59 patients,
48 were selected for reanalysis (Korea, n 5 16 [6];
Hong Kong, n 5 16 [13]; Japan, n 5 16 [14]). Patient
selection was based on availability from a historical
control group of patients who were matched according
to NKIPI risk group (risk score 0-1 vs 2-4) and disease
status at transplantation (first CR [CR1], second CR
[CR2] vs partial remission [PR]/no response [NR]),
at a ratio of 1:3. In cases where the NKIPI score was
not available at the time of analysis, only disease statuswas considered for matching criteria. The sources of
the matching control group were the lymphoma data
registry for each study group. The order of priority
in selection criteria for matched control cases was
NKIPI risk score, followed by disease status at trans-
plantation or conventional treatment/observation.
The matched control cases (n5 107) received conven-
tional chemotherapy with or without RT (n5 34), RT
alone (n 5 5) as salvage therapy, or observation (n 5
68) at CR1 or CR2 as postremission care instead of
HDC/autologous HSCT. All patients had pathologi-
cally confirmed NK/T cell lymphoma according to
the WHO classification [1]. One patient with negative
Epstein-Barr virus (EBV) in situ hybridization from
the HSCT group was excluded from the final analysis;
thus, the group from Japan included 15 patients.
Extranasal NK/T cell lymphoma was defined as
described previously [3]. In brief, upper aerodigestive
tract NK/T cell lymphoma (UNKTL) was defined as
that involving the nasal cavity, nasopharynx, and
the upper aerodigestive tract, whereas extra-upper
aerodigestive tract NK/T cell lymphoma (EUNKTL)
included lymphomas occurring at all other sites [3].
The following clinical data were collected from the
medical records: demographic information, LDH
level at diagnosis, initial Ann Arbor stage, IPI at diag-
nosis, NKIPI at diagnosis, presence or absence of B
symptoms, performance status, date of diagnosis,
date of autologous HSCT, disease status at transplan-
tation, transplantation outcome, salvage treatment
type and outcome, date of last follow-up, and cause
of death. The study design was approved by the Sam-
sung Medical Center’s Institutional Review Board.
Chemotherapy
Each patient received 1 of the following initial treat-
ment modalities: (1) an anthracycline-containing che-
motherapeutic regimen with or without RT (n5 125),
(2) a non–anthracycline-containing chemotherapeutic
regimen with or without RT (n5 15), (3) involved-field
RT (IFRT) as the primary treatment (n 5 13), or (4)
surgery plus RT (n5 1). Anthracycline-based regimens
used includedCHOP(cyclophosphamide, (Cy) doxoru-
bicin, vincristine, and prednisolone; n5 68), dose-esca-
lated CHOP (deCHOP; n 5 1), velCHOP (velcade
plus CHOP; n5 1), CEOP (Cy, epirubicin, vincristine,
and prednisolone; n 5 14), CEOP/ProMACE (CEOP
followed by Cy, doxorubicin, etoposide, and predni-
sone; n5 4),MACOPB (methotrexate [MTX], doxoru-
bicin, Cy, vincristine, prednisone, and bleomycin; n 5
2), CHOEP (Cy, doxorubicin, vincristine, etoposide,
and prednisolone; n 5 6), ProMace (n 5 3), ProMace/
Cytabom (ProMace plus cytabarabine, bleomycin, vin-
cristine, MTX, and leucovorin; n 5 21), COPBLAM
(Cy, vincristine, prednisone, bleomycin, doxorubicin,
and procarbazine; n5 2), EPOCH (etoposide, doxoru-
bicin, vincristine, Cy, and prednisolone; n 5 1),
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1), and epi-COP (epirubicin, Cy, vincristine, predniso-
lone; n 5 1). The non–anthracycline-containing
regimens used were IMEP (ifosfamide, MTX, and eto-
poside; n5 3), ESHAP (etoposide,methylprednisolone,
cisplatin, and cytarabine; n 5 1), DHAP (dexametha-
sone, cytarabine, andcisplatin; n5 1),DeVIC (carbopla-
tin, etoposide, ifosfamide, and dextamethasone; n 5 1),
IMVP-16 (ifosfamide, MTX, and etoposide; n 5 2),
and VIPD (etoposide, ifosfamide, cisplatin, and dexa-
methasone; n 5 7). In patients with localized disease,
IFRT was given at the physician’s discretion after che-
motherapy. Treatment response was assessed according
to standard response criteria [19].
HDC/Autologous HSCT
The procedures for HDC and autologous HSCT
have been described previously [13,14,20]. In brief, the
following conditioning regimens were used: CBV
(etoposide, carmustine, and Cy; n 5 14), BEAM (car-
mustine, etoposide, cytarabine, and melphalan (Mel);
n5 12),MCEC (ranimustine, Cy, etoposide and carbo-
platin; n 5 8), BEAC (carmustine, etoposide, cytara-
bine, and Cy; n 5 2), Cy/TBI (Cy and total body
irradiation; n 5 2), VCT (etoposide, Cy and TBI;
n 5 2), and others (n5 7).
Statistical Analysis
Disease-specific survival and relapse-free survival
(RFS) were estimated using the Kaplan-Meier method.
Disease-specific survival was calculated from the date
of diagnosis to the date of death from the disease or
the last follow-up. RFS was calculated from the date
of CR to the first documented relapse in patients
who attained CR. Survival rates were compared for
statistical differences using log-rank analysis. Survival
rates were compared for statistical differences by using
log-rank analysis. Continuous biological variables
were dichotomized for log-rank analysis. A back-
ward-stepwise Cox regression analysis was performed
to delineate prognostic factors at themultivariate level,
and all hazard ratios (HRs) were adjusted for age.
P values\ .05 were considered statistically significant,
and all P values correspond to 2-sided significance
tests.RESULTS
Patient Characteristics
A total of 47 patients who underwent autologous
HSCT were compared with 107 matched controlled
cases. Baseline characteristics are summarized inTable
1. All clinical parameters except age and initial Ann
Arbor stage were relatively well balanced between
the control group and the study group. The median
time from diagnosis to transplantation was 8.8 months(range, 2.1 to 86.3months). The proportion of patients
under age 60 years was significantly higher in the au-
tologous HSCT group compared with the control
group (95.7% in the autologous HSCT group vs
72.0% in the control group; P 5 .001). In addition,
the proportion of patients with localized disease was
lower in the autologous HSCT group (66.0%) than
in the non-HSCT group (82.2%) (P 5 .038). Other-
wise, there were no significant differences in distribu-
tions of sex, performance status, LDH level, IPI risk
group, presence of B symptoms, anatomic category,
NKIPI risk group, or primary treatment modality
between the 2 groups.
Autologous HSCTOutcome
More than 90% of the patients in each group re-
ceived primary chemotherapy with or without IFRT
(Table 1). Approximately 2/3 of the patients received
CBV, BEAM, or MCEC as the conditioning regimen
before HSCT. Of the HSCT group, 30% (n 5 14)
were in CR1, 28% (n 5 13) were in CR2, 28% (n 5
13) were in PR/SD, and 15% (n 5 7) were in PD at
the time of transplantation. Using an intent-to-treat
analysis, 66.0% (n 5 31) attained CR after HSCT,
4.3% (n 5 2) attained PR, and 19.1% (n 5 9) had
PD. Four fatal toxicities were observed, with a treat-
ment-related mortality (TRM) rate of 8.5% (septic
shock, n 5 1; pneumonia, n 5 1; unspecified, n 5 2).
Of the 31 patients who attained CR after HSCT, 13
(41.9%) experienced relapse; the median RFS from
the date of CR to the first documented relapse or fol-
low-up was 23.3 months (range, 0.2 to 180.3 months).
Of the 13 patients who experienced relapse, 5 received
salvage chemotherapy, 4 received RT, 2 underwent
allogeneic HSCT, and 2 received palliative treatment.
After a median follow-up of 99.8 months post-HSCT
(range, 23.4 to 180.9 months), the median survival
time after HSCT has not yet been reached. There
was no significant difference in survival between the
HSCT and control groups (56.2% vs 47.6%;
P 5 .127) (Figure 1B).
Prognostic Analysis for Autologous HSCT
The following clinical factors predicted poor sur-
vival of patients undergoing autologous HSCT in uni-
variate analysis: advanced Ann Arbor stage (stage III/
IV; P 5 .045) and disease status at the time of trans-
plantation (non-CR; P\.001) (Table 2). For RFS after
autologous HSCT, advanced Ann Arbor stage (stage
III/IV; P 5 .021), elevated LDH level (P 5 .026),
non-CR at the time of transplantation (P 5 .001),
and high IPI risk group (high-intermediate/high;
P 5 .005) predicted relapse after HSCT. In multivari-
ate analysis with stage, the presence of B symptoms, an-
atomic category, and disease status at HSCT, only
disease status at HSCT retained its statistical signifi-
cance for RFS (P\.001; HR 5 3.5; 95% confidence
Table 1. Patient and Treatment Characteristics
All Patients HSCT Controls P Value
Total cases, n (%) 154 (100) 47 (30.5) 107 (69.5)
Median age, years (range) 47 (17 to 80) 42 (17 to 62) 52 (17 to 80)
Age, years, n (%)
# 60 122 (79.2) 45 (95.7) 77 (72.0) .001
> 60 32 (20.8) 2 (4.3) 30 (28.0)
Sex, n (%)
Male 111 (72.1) 34 (72.3) 77 (72.0) .962
Female 43 (27.9) 13 (27.7) 30 (28.0)
Performance status, n (%)
ECOG 0-1 139 (90.3) 43 (91.5) 96 (89.7) .733
ECOG 2-4 15 (9.7) 4 (8.5) 11 (10.3)
Ann Arbor stage, n (%)
Limited (I-II) 118 (77.1) 31 (66.0) 87 (82.2) .038
Advanced (III-IV) 36 (23.5) 16 (34.0) 20 (17.8)
LDH (n 5 150), n (%)
# Upper limit of normal 77 (51.3) 23 (51.1) 54 (51.4) .972
> Upper limit of normal 73 (48.7) 22 (48.9) 51 (48.6)
IPI risk group (n 5 151), (%)
Low/low-intermediate 127 (84.1) 37 (82.2) 90 (84.9) .680
High-intermediate/high 24 (15.9) 8 (17.8) 16 (15.1)
B symptoms, n (%)
Positive 97 (63.0) 27 (57.4) 70 (65.4) .345
Negative 57 (37.0) 20 (42.6) 37 (34.6)
Anatomic category, n (%)
UNKTL 141 (91.6) 42 (89.4) 99 (92.5) .516
EUNKTL 13 (8.4) 5 (10.6) 8 (7.5)
NKIPI risk group (n 5 145), n (%)
Low risk (group 1-2) 80 (55.2) 23 (54.8) 57 (55.3) .949
High risk (group 3-4) 65 (44.8) 19 (45.2) 46 (44.7)
Primary treatment, n (%)
Anthracycline-based chemotherapy ± RT 125 (81.2) 41 (87.2) 84 (78.5)
Non-anthracycline-based chemotherapy ± RT 15 (9.7) 3 (6.4) 12 (11.9) .600
RTonly 13 (8.4) 3 (6.4) 10 (10.2)
Surgical excision + RT 1 (0.6) 0 (0.0) 1 (0.8)
Disease status at treatment, n (%)
CR1 61 (39.6) 14 (29.8) 47 (43.9)
CR2 34 (22.1) 13 (27.7) 21 (19.6) .232
PR/NR/PD 59 (38.3) 20 (42.6) 39 (36.4)
NKIPI indicates natural killer/T cell lymphoma International Prognostic Index; UNKTL, upperaerodigestiveNK/Tcell lymphoma; EUNKTL, extra-upperaero-
digestive NK/T cell lymphoma; RT, radiotherapy; CR1, first complete response; CR2, second complete response; PR, partial response; NR, no response; PD.
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(P \.001; HR 5 7.2; 95% CI 5 4.4 to 1.6). Thus,
disease status at autologousHSCTwas themost impor-
tant prognostic factor for survival and RFS.Figure 1. Survival of all patients (A) anImpact of HSCTon Survival in NK/T Cell
Lymphoma
After a median follow-up of 116.5 months (range,
13.2 to 234.0 months), the median survival was 47.3d survival according to HSCT (B).
Table 2. Univariate Analysis for the Patients with HSCT
Relapse-Free Survival Disease-Specific Survival
Parameters Median (95% CI), Months P Value Median (95% CI), Months P Value
Age, years
# 60 13.7 (0.0 to 30.8) .600 NA NA
> 60 NA
Ann Arbor stage
Limited (I/II) NR .021 NR .045
Advanced (III/IV) 4.2 (0.0 to 9.3) 36.5 (11.0 -62.0)
LDH
# Upper limit of normal NR .026 NR .145
> Upper limit of normal 6.2 (0.0 to 29.8) 31.8 (0.0 to 104.4)
B symptoms
Positive 16.8 (0.0 to 44.4) .654 NR .536
Negative 19.3 (0.0 to 43.6) NR
Anatomic category
UNKTL 16.8 (0.0 to 34.6) .527 NR .152
EUNKTL 2.2 (1.3 to 3.2) 36.5 (0.0 to 73.5)
Disease status at HSCT
CR NR .001 NR <.001
Non-CR 2.5 (1.7 to 3.4) 19.2 (0.0 to 56.5)
IPI risk group
Low/low-intermediate 21.0 .005 NR .223
High-intermediate/high 1.8 (1.2 to 2.4) 19.2 (0.0 to 81.0)
NKIPI risk group
Low risk (group 1-2) NR .086 NR .066
High risk (group 3-4) 6.2 (0.0 to 20.1) 31.1 (0.0 to 70.7)
NA indicates not applicable; ; NKIPI indicates natural killer/T cell lymphoma International Prognostic Index; UNKTL, upper aerodigestive NK/T cell
lymphoma; EUNKTL, extra-upper aerodigestive NK/T cell lymphoma; RT, radiotherapy; CR, complete response; NR, no response; LDH, lactate de-
hydrogenase; HSCT, hematopoietic stem cell transplantation.
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(Figure 1A). The median survival time had not yet
been reached for the HSCT group, but it was 43.5
months for the control group (95% CI 5 6.7 to 80.3
months; P 5 .127, log-rank test) (Figure 1B). For all
patients in both groups, the clinical factors signifi-
cantly predicting unfavorable survival in univariate
analysis were performance status (Eastern Cooperative
Oncology Group [ECOG] 2 to 4; P5 .042), advanced
Ann Arbor stage (stage III/IV; P5 .02), elevated LDH
level (P 5 .010), anatomic category (EUNKTL; P 5
.017), disease status at treatment (non-CR; P\ .001),
IPI (high-intermediate/high; P 5 .027), and NKIPI
(group 3-4; P 5 .003) (Table 3).
Clinical parameters included in the multivariate
analysis were performance status (0 to 1 vs $ 2), Ann
Arbor stage (I/II vs III/IV), LDH level (normal vs ele-
vated), anatomic category (UNKTL vs EUNKTL),
disease status at treatment (CR1/CR2 vs non-CR),
and HSCT versus non-HSCT. A backward-condi-
tional Cox regression model was used. Significant
prognostic factors for survival in all patients were
LDH level (P 5 .005; HR 5 2.0; 95% CI 5 1.2 to
3.2), disease status at treatment (P 5\ .001; HR 5
7.8; 95% CI 5 4.6 to 13.0), and HSCT (P 5 .006;
HR 5 2.1; 95% CI 5 1.2 to 3.7) (Table 4).
Influence of Autologous HSCTon Survival in
Subgroup Analyses
We performed subgroup analyses in an attempt to
identify patients who would potentially benefit fromHSCT. In those patients who were in CR1 or CR2 at
the time of HSCT or surveillance after remission,
disease-specific survival rates were significantly higher
in the HSCT group compared with the control group
(disease-specific 5-year survival rate, 87.3% for HSCT
vs 67.8% for non-HSCT; P 5 .027, log-rank test)
(Figure 2A). We also performed subgroup analyses ac-
cording to NK-IPI risk group (low risk vs high risk)
(Figure 2B, C). In the low-risk group (group 1-2), there
was no significant difference in survival between the
HSCT and control groups (disease-specific 5-year sur-
vival rate, 86.7% for HSCT [n5 16] vs 69.1% for non-
HSCT [n5 38]; P5 .291, log-rank test) (Figure 2B). In
the high-risk group (group 3-4), however, the HSCT
group (n 5 6) seemed to have more favorable clinical
course compared with the control group (n 5 27) in
terms of survival with marginal statistical significance
(disease-specific 5-year survival rate, 100% vs 51.2%;
P5 .053, log-rank test) (Figure 2C). For those patients
who were in PR at the time of HSCT or other treat-
ment, there was no difference in survival between the
HSCT group and the control group (disease-specific
5-year survival rate, 29.6% vs 22.2%; P 5 .472, log-
rank test) (data not shown).
Subgroup analyses on non-CR patients at the time
of HSCT or non-HSCT treatment (chemotherapy
with or without RT or RT alone) revealed no signifi-
cant difference in disease-specific survival rates be-
tween the HSCT and control groups (1-year survival
rate, 66.7% vs 28.6%; P 5 .141, log-rank test)
(Figure 3A). Further subgroup analyses demonstrated
Table 4. Multivariate Analysis for Disease-Specific Survival of
All Patients
Parameters
Relative
Risk 95% CI P value
Performance status: ECOG 0-1 versus 2-4 0.6 0.3 to 1.4 .233
Ann Arbor stage: I/II versus III/IV 1.6 0.9 to 2.8 .129
LDH: # Upper limit of normal versus > upper
limit of normal
2.0 1.2 to 3.2 .005
Anatomic category: UNKTL versus EUNKTL 1.4 0.6 to 3.0 .457
Disease status at HSCTor chemotherapy: CR
versus non-CR
7.8 4.6 to 13.0 <.001
HSCT: Yes versus no 2.1 1.2 to 3.7 .006
NA indicates not applicable; NKIPI indicates natural killer/T cell lym-
phoma International Prognostic Index; UNKTL, upper aerodigestive
NK/T cell lymphoma; EUNKTL, extra-upper aerodigestive NK/T cell
lymphoma; RT, radiotherapy; CR, complete response; NR, no response;
LDH, lactate dehydrogenase; HSCT, hematopoietic stem cell transplan-
tation.
Table 3. Univariate Analyses for Disease-Specific Survival of
All Patients
Parameter Median (95% CI), Months P Value
Age, years
# 60 62.4 (22.6 to 102.2) .901
> 60 33.5 (19.5 to 42.4)
Performance status
ECOG 0-1 66.8 (7.4 to 87.2) .042
ECOG 2-4 36.5 (0.0 to 77.2)
Ann Arbor stage
Limited (I/II) NR .002
Advanced (III/IV) 25.0 (3.2 to 46.9)
LDH
# Upper limit of normal NR .010
> Upper limit of normal 31.1 (6.6 to 55.5)
B symptoms
Positive 36.7 (0.0 to 78.1) .631
Negative 66.8 (21.1 to 112.6)
Anatomic category
UNKTL 78.8 (42.1 to 115.4) .017
EUNKTL 19.2 (10.1 to 28.4)
HSCT
Yes NR .127
No 43.5 (6.7 to 80.3)
Disease status at HSCTor
chemotherapy
CR NR <.001
Non-CR 10.8 (8.0 to 13.7)
IPI risk group
Low/low-intermediate 79.6 (20.2 to 104.6) .027
High-intermediate/high 25.0 (0.2 to 49.9)
NKIPI risk group
Low risk (group 1-2) NR .003
High risk (group 3-4) 30.9 (10.5 to 51.3)
NA indicates not applicable; NKIPI indicates natural killer/Tcell lymphoma
International Prognostic Index; UNKTL, upper aerodigestive NK/T cell
lymphoma; EUNKTL, extra-upper aerodigestive NK/T cell lymphoma;
RT, radiotherapy; CR, complete response; NR, no response; LDH, lactate
dehydrogenase; HSCT, hematopoietic stem cell transplantation.
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non-CR patients when subcategorized into low-risk
and high-risk NK-IPI groups (Figures 3B and C).DISCUSSION
This study represents the first multinational col-
laborative study exploring the role of HDC and
HSCT in the treatment of patients with NK/T cell
lymphomas. Although HSCT to treat other types of
lymphomas (especially diffuse large B cell lymphoma)
has been studied extensively, the definite role of and
specific indications for HSCT in treating NK/T cell
lymphomas have not yet been systematically estab-
lished. We and few other groups have previously re-
ported poor survival outcome in patients with NK/T
cell lymphomas [3-6]. Although several studies have
investigated the role of HSCT in treating NK/T cell
lymphomas [13-17], they could not conclusively dem-
onstrate the survival benefit fromHSCT due to a small
number of patients and the lack of a control arm. To
overcome these obstacles, we undertook a multina-
tional, multicenter matched control study to deter-
mine the potential survival benefit of HSCT intreating NK/T cell lymphomas, as well as to identify
subgroups of patients who might benefit the most
from HSCT.
Our data reveal several interesting findings. There
was a trend toward better survival in the HSCT pa-
tients compared with the historical control group, al-
though the difference was not statistically significant
(disease-specific 5-year survival rate, 56.2% for
HSCT vs 47.6% for non-HSCT; P 5 .127). The im-
pact of HSCT on survival was significantly retained at
multivariate level, with a 2.1-fold (95% CI 5 1.2 to
3.7) reduced risk of death (P 5 .006). The most im-
portant prognostic factor influencing RFS and sur-
vival after HSCT was disease status at the time of
transplantation (P \ .001) (Table 2). Patients who
did not attain CR at the time of transplantation had
a 7.2-fold (95% CI5 4.4 to 11.6) greater risk of death
compared with those who were in CR (data not
shown).
Furthermore, disease-specific survival was signifi-
cantly better in patients in CR in the HSCT group
compared with those in the control group (disease-
specific 5-year survival rate, 87.3% vs 67.8%; P 5
.027). The report of the International Consensus Con-
ference on High-Dose Therapy with Hematopoietic
Stem Cell Transplantation in Aggressive Non-Hodg-
kin’s Lymphomas recommended front-line HSCT
only in patients who achieve CR [21]. In particular,
the patients with high NKIPI demonstrated notably
improved survival after undergoing HSCT
(Figure 2C), although the small number of cases in
this subgroup limited the statistical power (P 5
.053). These patients need longer follow-up to allow
any conclusions to be drawn on the statistical signifi-
cance in survival difference. Based on our findings,
we suggest that HSCT should be carefully considered
for postremission consolidation therapy in patients
with NK/T cell lymphomas, especially those with
high NKIPI risk scores.
Figure 2. A) OS according to HSCT in CR patients, B) Impact of HSCTon survival of the low NKIPI group (CR), C) Impact of HSCTon survival of the
high NKIPI group (non-CR).
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at the time of HSCT or non-HSCT treatment found
that disease-specific survival rates were not signifi-
cantly prolonged in the HSCT group compared with
the control group (1-year survival rate, 66.7% vs
28.6%; P5 .141 [Figure 3A]. This finding is in agree-
ment with previous studies that found negative out-
comes of transplantation in a refractory disease state
[20,22-24]. The segregation of patients based on
NKIPI was not statistically significant in non-CR pa-
tients, although a trend toward better survival was
seen in those patients with higher NKIPI who under-
went autologous HSCT (P 5 .064; Figure 3C).
Whether or not HSCT should be considered in pa-
tients with refractory NK/T cell lymphomas, espe-
cially those with high NKIPI scores, remains to be
determined. Our findings do suggest that patients
with refractory NK/T cell lymphomas should be of-
fered therapy with investigational agents or reduced-
intensity allogeneic HSCT in the context of clinical
trials.
Although HDC/HSCT seemed to confer a
survival advantage in our patients with NK/T celllymphomas, especially those in the high-risk NKIPI
group, only 66% of the patients receiving HDC/
HSCT achieved CR, of whom 41.9% (n 5 12) even-
tually experienced relapse. In addition, the role of
HDC/HSCT was not definite in the patients with
PR (disease-specific 5-year survival rate, 29.6%
HSCT vs 22.2% for non-HSCT; P 5 .472).
A possible explanation for the low CR rate and
high relapse rate may be the inefficiency of the con-
ditioning regimens used. Analyzing the efficacy of
the conditioning regimen in this study is difficult be-
cause of the heterogeneity of the treatment protocols
used. Nevertheless, most of the patients received a
Cy-based conditioning regimen, which could be
a target for a multidrug-resistance gene. Allogeneic
HSCT possibly can have a graft-versus-lymphoma ef-
fect and reduce relapse rate at the expense of high
TRM [25,26]. Another possible strategy to improve
the treatment outcome of HDC/HSCT may be to
perform transplantation before chemotherapy resis-
tance is allowed to progress, such as when the patient
is in CR1 [27]. Consequently, more multinational
prospective studies incorporating novel therapies
Figure 3. A) OS according to HSCT in non-CR patients, B) Impact of HSCTon survival of the low NKIPI group (non-CR), C) Impact of HSCTon survival
of the high NKIPI group (non-CR).
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patients.
Despite the adoption of a matched control design
to minimize potential biases, our study is still limited
by the retrospective nature of the analyses. To reduce
bias, we matched 2 known prognostic factors known
to influence survival in NK/T cell lymphomas: dis-
ease status at time of transplantation and NKIPI.
Previous studies have confirmed the attainment of
CR at the time of transplantation as one of the
most powerful prognostic factors for survival after
HSCT [15,19,20,23,28]. Thus, we selected a 1:3 ratio
of HSCT patients to control patients who did not un-
dergo HSCT as postremission consolidation therapy,
but had surveillance alone. For the patients who did
not achieve CR at the time of HSCT, we attempted
to select control patients who received conventional
therapy from the database. There are potential selec-
tion biases in the historical control group. The pa-
tients in the control group did not undergo HSCT
mainly due to different practice guidelines amongthe institutions in the 3 different nations and differ-
ences in patient age. Moreover, the proportion of pa-
tients with non-CR (PR/SD/PD) was higher in the
HSCT group, likely reflecting current treatment
practices. But the clinical variables, including perfor-
mance status, LDH level, IPI, presence of B symp-
toms, anatomic category, NK-IPI, disease status,
and primary treatment modalities, were well balanced
between the 2 arms. There were greater proportions
of patients under age 60 years, but the prognostic im-
pact of this was not significant at the univariate level
(Table 2), which coincides with results from the Jap-
anese and Korean series [6,14,29]. Another weakness
of the present study lies in the heterogeneity of the
treatment modalities and HSCT protocols owing to
retrospective data collection from 3 different data-
bases from different institutions and different nations.
In summary, collectively, our data indicate that
HSCT seemed to confer a survival benefit in patients
who attained CR as postremission consolidation ther-
apy. These findings suggest that, in particular, patients
1364 Biol Blood Marrow Transplant 14:1356-1364, 2008J. Lee et al.with high NKIPI risk scores (group 3-4) at diagnosis
who attain CR should receive full consideration for au-
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